Next-generation HBV Therapeutics: Emerging Therapies and Search for Functional Cure | AASLD

Next-generation HBV Therapeutics: Emerging Therapies and Search for Functional Cure

Nov 09 2025
Convention Center: Room 207, Level 2
5:00 PM - 6:30 PM

World Class Speakers

Grace Lai-Hung Wong, MD, MBChB (Hons), FRCP, FHKCP, FHKAM
Abstract Presenter

Grace Lai-Hung Wong, MD, MBChB (Hons), FRCP, FHKCP, FHKAM

The Chinese University Of Hong Kong
Edward J Gane, MD, FAASLD
Abstract Presenter

Edward J Gane, MD, FAASLD
Barbara Testoni, PhD
Abstract Presenter

Barbara Testoni, PhD

Inserm UMR 1350, University of Lyon 1, IHU EVEREST
Harry LA Janssen, MD, PhD, FAASLD
Moderator

Harry LA Janssen, MD, PhD, FAASLD

Erasmus MC, University Medical Center Rotterdam
Barbara Testoni, PhD
Moderator

Barbara Testoni, PhD

Inserm UMR 1350, University of Lyon 1, IHU EVEREST

Description

This session will feature translational and early-phase clinical studies that are advancing the therapeutic landscape for chronic hepatitis B. Highlights include a novel capsid assembly modulator, early stage HBV immune modulation trial, therapeutic vaccines, antisense oligonucleotides in combination with pegylated interferon, and a preclinical study of an epigenetic editing agent demonstrating HBV surface antigen loss through targeted DNA methylation. Together, these studies showcase innovative pathways toward viral suppression and functional cure.
 

Journey Maps

Presentations

5:00 PM - 5:15 PM
Oct 09 2026
Convention Center - Room 207, Level 2

CD4-Dependent Mechanisms Drive HEPLISAV-B Mediated HBsAg Clearance and Anti-HBV Immunity in Chronic HBV Carrier Mice

Grace Lai-Hung Wong, MD, MBChB (Hons), FRCP, FHKCP, FHKAM , Abstract Presenter
Hepatitis
5:15 PM - 5:30 PM
Oct 09 2026
Convention Center - Room 207, Level 2

HBsAg declines observed with VRON-0200 alone are rapidly enhanced with the addition of combination antiviral therapies: results from a Phase 1b study for functional cure in chronically HBV-infected patients

Grace Lai-Hung Wong, MD, MBChB (Hons), FRCP, FHKCP, FHKAM , Abstract Presenter
Hepatitis
5:30 PM - 5:45 PM
Oct 09 2026
Convention Center - Room 207, Level 2

Safety, Tolerability, Immunogenicity, and Antiviral Efficacy of GS-2829 and GS-6779, a Novel, Arenaviral-Vectored, Therapeutic Hepatitis B Vaccine: Results From a Phase 1b Study in Virally Suppressed Patients With Chronic Hepatitis

Edward J Gane, MD, FAASLD , Abstract Presenter
Hepatitis
5:45 PM - 6:00 PM
Oct 09 2026
Convention Center - Room 207, Level 2

Oral Once -Daily 300 mg ALG-000184, a Novel Capsid Assembly Modulator Demonstrates potent suppression of HBV DNA in Treatment-Naive or Currently-not -treated Subjects with Chronic HBV

Barbara Testoni, PhD , Abstract Presenter
Hepatitis
6:00 PM - 6:15 PM
Oct 09 2026
Convention Center - Room 207, Level 2

Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chronic hepatitis delta virus infection: Week 48 endpoint results from the Phase 2 SOLSTICE trial

Grace Lai-Hung Wong, MD, MBChB (Hons), FRCP, FHKCP, FHKAM , Abstract Presenter
Hepatitis
6:15 PM - 6:30 PM
Oct 09 2026
Convention Center - Room 207, Level 2

HBV Entry Inhibitor Reverses Resistance to Pegylated Interferon in HBeAg-Positive Chronic Hepatitis B Patients: Results from a Phase II Multicenter Double-blind Randomized Trial of Hepalatide

Barbara Testoni, PhD , Abstract Presenter
Hepatitis

Objectives

  • Describe emerging therapeutic strategies for chronic HBV, including mechanisms targeting capsid assembly, immune restoration, and epigenetic regulation
  • Evaluate novel approaches to HBV including antisense oligonucleotides, monoclonal antibodies, and therapeutic vaccines
  • Interpret preclinical and early-phase trial data to understand their potential impact on future viral hepatitis treatment paradigms